



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61L	A2	(11) International Publication Number: WO 99/02195 (43) International Publication Date: 21 January 1999 (21.01.99)
(21) International Application Number: PCT/US98/10678 (22) International Filing Date: 26 May 1998 (26.05.98) (30) Priority Data: 60/051,861 7 July 1997 (07.07.97) US 08/912,762 18 August 1997 (18.08.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US Not furnished (CIP) Filed on Not furnished (71) Applicant (for all designated States except US): IMPLANT SCIENCES CORPORATION [US/US]; 107 Audubon Road #5, Wakefield, MA 01880-1246 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): ARMINI, Anthony, J. [US/US]; 5 Skytop Drive, Manchester, MA 01944 (US). (74) Agents: BLODGETT-FORD, Sayoko, J. et al.; Foley, Hoag & Eliot LLP, One Post Office Square, Boston, MA 02109 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>Without international search report and to be republished upon receipt of that report.</i>
(54) Title: CORONARY STENT WITH A RADIOACTIVE, RADIOPAQUE COATING (57) Abstract <p>A stent according to the systems and methods described herein may include a body formed from a non-radioactive structural material, a radiopaque material coating the body, and a beta-emitting radioisotope ion implanted into the radiopaque material. Optionally, an adhesion layer, such as titanium, vanadium, chromium, ion, cobalt, nickel, or some combination or alloy thereof, may be applied to the body to facilitate adhesion of the radiopaque material. The radiopaque material may include platinum, iridium, rhenium, gold, tantalum, or some combination or alloy thereof. The beta-emitting radioisotope may include sulfur-35 or phosphorous-32 and may be ion implanted into the radiopaque material.</p> <div data-bbox="682 1176 1315 1470" data-label="Image"> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5 **CORONARY STENT WITH A RADIOACTIVE, RADIOPAQUE COATING**

Technical Field

This invention relates to the field of intra-arterial stents used to restore patency to coronary arteries and more specifically to radioactive stents with improved x-ray visibility.

Background of the Invention

10 After balloon angioplasty, a metal tubular scaffold structure called a stent may be permanently implanted to physically hold open the repaired coronary artery. Unfortunately, up to 30% of such procedures result in reclosure (restenosis) of the artery within six months to one year. One solution to the problem is to provide acute local, postoperative radiation treatment of the site using a catheter tipped with iridium-192 radioisotope. In this method
15 the iridium-192 tipped catheter is placed at the arterial site for thirty to forty minutes after stent deployment and then retracted. This type of acute high dose treatment using gamma radiation has been found to substantially reduce the rate of subsequent restenosis, as noted in Wiedermann, J.G. et al., "Intracoronary Irradiation Markedly Reduces Restenosis After Balloon Angioplasty in a Porcine Model," 23 J. Am. Coll. Cardiol., 1491-1498 (May 1994)

5 and Tierstein, P.S. et al., "Catheter-Based Radiotherapy to Inhibit Restenosis After Coronary Stenting," 336 New England Journal of Medicine, 1697-1703 (June 12, 1997).

An alternate method of addressing the restenosis problem is to form the structural material of the stent itself from a radioactive material as described by Fischell R. et al. in U.S. Patent 5,059,166 (the '166 patent) and in U.S. Patent 5,376,617 (the '617 patent). The
10 '166 and '617 patents also describe a method of electroplating a radioactive material on the structural material of the stent. Each of these methods has certain drawbacks. Placement of radioactive material within the structural material of the stent can deteriorate the physical properties of the structural material, such as stiffness, and can present fabrication difficulties with respect to radiation exposure of workers during the manufacturing process. The
15 electroplating process, on the other hand, may result in poor adhesion of the radioactive material, which could delaminate during insertion.

Moreover, an additional requirement for any clinically useful stent is that it should have good x-ray visibility. A fairly thick (ten to fifteen micron) radiopaque coating of a high density, high atomic number metal such as gold, platinum, or iridium may be coated on
20 the structural material of the stent in order to achieve visibility in an x-ray. Placing the radioactivity within the structural material, as taught by the '166 and '617 patents, may preclude coating the stent with a radiopaque metal. A high density metal that is approximately fifteen microns thick will absorb and reduce the kinetic energy of beta rays emitted from the structural material under the coating.

25 Further, the '166 and the '617 patents mention the possibility of plating the radioisotope Au¹⁹⁸ on the structural material of the stent. It is highly unlikely that plating of

5 Au¹⁹⁸ would make the stent radiopaque because the coating would be less than a few
angstroms thick. As noted by Fischell et al. in the article "Low-Dose β -Particle Emission
From 'Stent' Wire results in Complete, Localized Inhibition of Smooth Muscle Cell
Proliferation", 90 Circulation 2956-2963 (1994) (the Fischell article), radioactivity on the
order of one microcurie is preferred for a coronary stent. Using an Au¹⁹⁸ plating solution
10 containing typically 18Ci/g of dissolved gold (following a two-week cooldown period after
activation in a nuclear reactor), a total activity of 1 μ Ci would require a total coating mass of
0.055 μ g, which, when distributed over the surface of an entire coronary stent, would have a
thickness of about one monolayer of gold. Such a thin layer would not add contrast in an x-
ray picture of the stent. Moreover, Au¹⁹⁸ is not a pure beta ray emitter, it has numerous
15 gamma rays, which may give a radioactive dose to the entire body of a patient instead of a
localized dose to a target area in the coronary artery. Au¹⁹⁸ also has a half-life (2.7 days)
that is too short to be practical for an intra-arterial coronary stent.

Another method mentioned in the Fischell article and further investigated by Laird,
J.R. et al., in "Inhibition of Neointimal Proliferation with Low-Dose Irradiation from β -
20 Particle Emitting Stent," 90 Circulation 529 (1996) (the Laird article), is to impregnate
titanium stents with up to thirty atomic percent of stable phosphorous and subsequently
activate the entire stent in a nuclear reactor to form the radioisotope P³¹ within the titanium
structural material. One of the disadvantages of the Laird method is that the massive
quantity (30 at. %) of phosphorous required to make even 0.15 microcurie of P³¹ may
25 severely alter the structural strength of the stent itself.

5 The references discussed above do not suggest any way to adapt the radioactive stent
embodiments of the '166 and '617 patents and also make the stent radiopaque. In the
preferred embodiment of the '166 and '617 patents, the structural material is doped with an
activatable element and then made radioactive in a nuclear reactor. The resulting
radioactive stent would be extremely difficult to subsequently sputter coat with a thick (up
10 to 15 micron) coating of gold. The radiation safety challenges for the factory workers would
be considerable and would therefore render the technique impractical for mass production
purposes. In addition, the sputter cleaning process, which would generally be necessary to
achieve good adhesion, could emit radioactive structural material and contaminate the inside
walls of the coating apparatus.

15

 If the radiopaque metal is coated first and the coated stent is then placed in a nuclear
reactor, the coating could activate gamma emitting isotopes to curie levels and render the
stent undesirable for human use. For example, the thermal neutron reaction cross section
for a gold radiopaque coating is 198 barns, which could activate a 15 μ m thick gold coating
20 to 10 tens of curies in a one week of irradiation.

 Similar problems arise if the radioisotope is plated on the structural material of the
stent, which is the alternate embodiment mentioned in the '166 and '617 patents. For this
alternate embodiment, the sputter cleaning step prior to the radiopaque material coating
could remove the radioactive material and distribute it throughout the inside walls of the
25 coating apparatus. Gold is a very inert metal. As a result, if the gold is coated on the
structural material first and then the radioactive material is plated on the gold outer surface,
it could be extremely difficult to get the plating to adhere. The preferred radioactive plating

5 of phosphorous-32 generally cannot be plated onto gold. The only radioisotope which can readily plate on gold is Au¹⁹⁸, but, as noted above, Au¹⁹⁸ is a gamma and beta ray emitter with a half-life (2.7 days) that is too short to be of clinical interest.

A method of plating a stent with a high density, radiopaque metal or alloy is disclosed in U.S. Patent No. 5,607,442 to Fischell et al. (the '442 patent). The '442 patent
10 describes a stent that is plated on its longitudinal wires with a radiopaque metal with a sufficient thickness so that the longitudinal wires will be clearly radiopaque in fluoroscopy. The circumferential wires of the stent are described as being plated with a much lesser thickness than the longitudinal wires so that they will not be distinctly radiopaque. The '442 patent describes the purpose of coating the longitudinal wires as being to assist the
15 cardiologist in determining whether the stent has been fully and uniformly deployed throughout its entire length, thereby obviating the need for use of an intravascular ultrasound catheter. The '442 patent describes the purpose of coating the circumferential wires as being to avoid electrolytic corrosion of the stent by using a single metal outer coating on all stent surfaces, and, when plating with gold, to provide an attractive
20 appearance for the stent. The '442 patent suggests that the circumferential wires should not be radiopaque because, if all the stent wires are radiopaque, such as if the stent is made from tantalum, then the stent may be so radiopaque as to obscure some of the lumen within the implanted stent.

The '442 patent also mentions in passing that the stent could include a radioisotope
25 that is incorporated by ion implantation into the metal of the stent, or could include a radioisotope that is placed on the stent below an anti-thrombogenic coating. The '442

5 patent appears to indicate that the radioisotope should be ion implanted directly into the structural material of the stent. As noted above, ion implantation of radioactive material within the structural material of the stent can present fabrication difficulties. In addition, the high density radiopaque material plated on the longitudinal wires would absorb and reduce the kinetic energy of beta rays emitted from the structural material under the plating on the
10 longitudinal wires, thereby causing a disparity in the spatial distribution of the beta radiation, which would be more intense longitudinally than circumferentially. Such spatial nonuniformity generally would be less desirable for reducing hyperplasia than a uniform distribution.

Another significant disadvantage of the methods disclosed in the references
15 discussed above is the absence of any technique for assuring that the radiopaque coating sticks to the structural material of the stent. This disadvantage is particularly important when the radiopaque material is gold. In practice, gold plating, such as that disclosed in the '442 patent, cannot be electroplated directly onto stainless steel or nitinol. Moreover, the gold plating described in the '442 patent could be rubbed off during handling by medical
20 personnel as well as during, and subsequent to, placement in a patient's body. Gold flaking could interfere with the deployment of the stent. If, for example, a proportionally substantial amount of the radiopaque gold on a longitudinal wire were to flake off, it could suggest, falsely, to the interventional cardiologist that the stent had not fully expanded. The cardiologist could then decide, reasonably but mistakenly, to inflate a very high pressure
25 balloon within the stent, as disclosed in the '442 patent, in an attempt to correct the deployment of the stent. The stent also could be placed at the wrong position within the

5 artery because the stent's length appeared shorter under fluoroscopy due to flaking off of the gold plating.

These difficulties may be overcome and a stent that is both radiopaque and radioactive may be fabricated using the present invention.

Summary of the Invention

10 A stent according to the systems and methods described herein may include a body formed from a non-radioactive structural material, a radiopaque material coating the body, and a beta-emitting radioisotope ion implanted into the radiopaque material. The body of the stent may have a tubular mesh shape, a helical coil shape, or a variety of other shapes. Optionally, an adhesion layer may be coupled to the body and coupled to the radiopaque
15 material. The adhesion layer may be formed of a material that includes titanium, vanadium, chromium, iron, cobalt, nickel, or some combination or alloy thereof. The adhesion layer may include a transition metal or alloy, and may be between approximately 100 to 3000 angstroms thick.

Optionally, the body of the stent may include a longitudinal portion and a
20 circumferential portion, and the radiopaque material may be applied to coat both of the portions with substantially even thickness. The radiopaque material may include platinum, iridium, rhenium, gold, tantalum, or some combination or alloy thereof. The radiopaque material may be between approximately 1 micron and approximately 5 microns thick, or between approximately 1 micron and approximately 15 microns thick.

5 The beta-emitting radioisotope may emit substantially no alpha or gamma radiation, thereby facilitating use of the stent as an intra-arterial coronary stent. The beta-emitting radioisotope may include sulfur-35 or phosphorous-32. The beta-emitting radioisotope may be ion implanted to a depth of less than approximately 3000 angstroms into the radiopaque material, optionally with a source strength of between approximately 0.1
10 microcuries and 10 microcuries. The beta-emitting radioisotope may have a half life of less than approximately 100 days.

 A method of fabricating a stent may include forming the stent from a non-radioactive structural material, coupling a radiopaque material to the structural material, and ion implanting a beta emitting radioisotope into the radiopaque material. The method
15 may include coating the structural material with an adhesion layer and then coating the adhesion layer with the radiopaque material. Coupling the radiopaque material may include sputtering or electroplating the radiopaque material, or applying the radiopaque material as a coating with a thickness of less than approximately 15 microns. The method of fabricating may also include ion implanting the beta emitting radioisotope to a depth in
20 the coating of less than approximately 3000 angstroms.

Brief Description Of Drawings

FIG. 1 illustrates a side-view and a cross-section of a single wire of a tubular mesh stent according to the present invention.

5 FIG. 2 illustrates an enlarged cross-section of a single wire of a stent according to the present invention.

FIG. 3 shows an example of the depth distribution of a radioisotope P^{31} when implanted in the gold coating.

FIG. 4 is a schematic diagram of a cross-section of a custom made ion source for
10 use in connection with the present invention. Three extensible probes are shown in a retracted position for servicing of the ion source.

FIG. 5 is a schematic diagram of the ion source of FIG. 4 showing the extensible probes in an extended position for operation of the ion source.

15 FIG. 6 is a schematic diagram illustrating an alternate embodiment for a plasma chamber of a custom made ion source.

Detailed Description of the Preferred Embodiments

Current stents are typically made from relatively light stiff metals such as titanium,
20 nitinol, (50% Ti, 50% Ni) or stainless steel, which do not produce an adequate x-ray image in a fluoroscope device during the angioplasty procedure.

A gold coating of approximately ten to fifteen microns thick on the stent structural material may enhance the x-ray image significantly. Gold is a very soft metal, and a

5 thickness of ten to fifteen microns should not contribute additional structural stiffness to the stent. The structural material of the stent should have considerable stiffness in order to hold open the elastic artery.

In order to effect good adhesion of the gold coating to the stent, it is desirable to first coat the structure with a thin coating of chromium or titanium about 3000 angstroms thick
10 before depositing the thicker gold coating. Chromium has been found to promote adhesion of gold to stainless steel stents and titanium has been found to promote adhesion to nitinol stents. Both the adhesion promoting layer and the gold coating can be deposited using an unbalanced magnetron sputtering processing in vacuum.

The non-structural gold coating, however, may also be used as a host for the
15 radioisotope. The radioisotope may be ion implanted, carrier-free, into the gold coating about 100 to 3000 angstroms below the gold outer surface.

The reverse configuration, i.e. ion implanting the radioisotope in the structural material of the stent then coating the structural material with ten to fifteen microns of gold, would not be preferred because the beta radiation kinetic energy and particle flux exiting the
20 coating would be reduced due to the high atomic number (79) and high density of gold (19.3g/cm^3). In addition, the process used to coat the radioactive stent with gold includes a sputter etch step, which would be used to clean and prepare the surface for the two subsequent coatings. This sputter etch cleaning step could remove the surface radioactivity and distribute it throughout the inside walls of the process chamber. One of the significant

5 advantages of the unique configuration of the present invention is that the stent may be both radiopaque and radioactive with a beta emitting radioisotope.

A preferred process for fabricating the stent would be to form a cylindrical stent or tubular mesh stent from a non-radioactive structural material such as titanium, stainless steel, nitinol alloy or any other stiff alloy, sputter clean the alloy to remove the native oxides
10 and about 100 angstroms of metal, and then coat the structural material with approximately 3000 angstroms of chromium or titanium to promote good adhesion, then coat the adhesion layer with approximately twelve microns of pure gold in a vacuum using an unbalanced magnetron sputter process (equipment available from AJA International, Scituate, MA).

The gold coating may then be ion implanted with the pure beta ray emitting
15 radioisotope P^{32} to a depth of 800Å at the peak of its concentration. Figure 2 shows the detail of a single wire in the stent. For a one microcurie stent, the peak P^{32} concentration at 800 angstroms below the gold outer surface would be about 0.4 parts per million. Figure 3 shows the depth distribution of P^{32} atoms in the gold coating when implanted at 180 keV with a dose of 3×10^9 ions/cm², which produces one microcurie of radioactivity at the end of
20 the implantation process.

The process for ion implantation of a radioisotope, such as phosphorous-32, can be done using a semiconductor ion implanter such as is readily available from Eaton Corp., Beverly, MA or Varian Corp., Gloucester, MA. The radioactive starting material may be a gas that includes some phosphorous-32 radioisotope and is then fed into the gas inlet on the
25 ion source. This process, however, generally is impractical for mass production because of

5 the safety challenges involved in generating a radioactive ion beam in conventional semiconductor equipment using radioactive gases.

Ion sources in conventional ion implantation equipment need daily maintenance to replace consumed filaments and insulators. If the parts were also radioactive with phosphorous-32 containing gases, the operators could be exposed to toxic levels of radiation
10 within several weeks of operation. It is therefore desirable, for practical manufacture of radioactive stents using this invention, to design and fabricate a special-purpose dedicated ion implanter to practice this invention. Such an ion implanter could have a specially designed ion source so that the operator could be shielded from radiation exposure during routine maintenance. In addition, the ion implanter could have a specially designed vacuum
15 system to minimize the generation of radioactive pump oils.

Preferably, a custom made ion implanter could be used. The customized implanter could include a specially designed ion source with vacuum locks that permit the operator to change a filament or the radioactive charge without exposing the operator to excessive
20 radiation or venting the vacuum chamber. An example of such a special ion source is described below.

The components of the ion source that routinely require maintenance may be affixed onto extensible probes that can be passed into the ion source vacuum system and positioned into their appropriate locations in the source. When service is required, the components
25 may be removed. Typical ion source components include a cathode, a vaporizer, a sputter

5 target, an electrostatic electron reflector, an anode, and a plasma chamber. These components need not all be present in a given implementation of an ion source.

A cathode is a source of electrons and is commonly formed from a hot filament composed of tungsten or tantalum metal, although a so-called hollow cathode may also be employed. A vaporizer is a heated oven in which the radioactive feedstock may be placed.

10 There is typically a connection between the vaporizer and the plasma chamber of the ion source to permit passage of gas created by heating the feedstock. The vaporizer may also be located within the plasma chamber and use a variety of heating methods to heat the feedstock. Electrical resistance heating is typically employed when the vaporizer is external to the plasma chamber of the ion source while waste heat from operation of the source or

15 heat from ion bombardment may be employed when the source of feedstock vapor is within the plasma chamber.

A sputter target is an alternate source of feedstock vapor. Excess ions fill the plasma chamber and are made to bombard the sputter target because of an applied or induced voltage. Sputtering liberates surface atoms from the sputter target, effectively creating a

20 vapor of the feedstock. An electrostatic electron reflector is a surface that is isolated by electrical insulation so it is not directly connected electrically to the anode or cathode. However, plasma bombardment may indirectly induce a voltage relative to the anode or cathode.

5 The anode may be the plasma chamber itself or an independent electrode in the plasma chamber or ion source structure. The plasma chamber is a container in which the plasma created by the ion source is maintained prior to extraction and acceleration.

FIG. 4 illustrates an embodiment of a customized ion implanter ion source 10. The source 10 includes a vacuum chamber 30, a hot tungsten filament cathode 1000 that may become eroded with use, an electrostatic electron reflector 3000 having insulators 511c, 512c, 513c, 514c that may also become coated with conducting material, a vaporizer 2000 for a radioactive elemental solid phosphorus 70b, and a plasma chamber 4000. The cathode 1000 is on an extensible probe 24c. The vaporizer 2000 is on an extensible probe 24b. The electron reflector 3000 is on an extensible probe 24c. Three sealable transfer containers 22a-c, each having sealable openings 28a-c, provide the capacity for containing radiation and radioactive particulates in addition to maintaining an inert gas atmosphere during transfer to a service area. Other radiation shielding 41a, 42a, 41b, 42b, 43b, 41c, 42c may be used to protect individuals while transferring the transfer containers 22a-c. Three valved openings 38a-c on the vacuum chamber 30 seal the vacuum chamber 30 from air after the extensible probes 24a-c are retracted. All of the extensible probes 24a-c in FIG. 4 are shown in the retracted position. Preferably, the valved openings 38a-c on the vacuum chamber 30 can be sealed adequately to maintain the vacuum in the system. The ion source 10 also contains three bellows 27a-c surrounding the extensible probes 24a-c. Joints 60a-c may be used to fasten the sealable openings 28a-c to the valved openings 38a-c. A magnetic field may be superimposed on the plasma chamber 4000, emanating from ferrous material poles 51, 52. Hand-operated valves 61a-c may be connected to vacuum and inert gas venting connections 63a-c, which could connect to a combined external pumping/venting

5 assembly (not shown). Preferably, the removable enclosures 20a-c will have a minimum of extra hardware attached so they will be easier to lift.

The customized ion source 10 may be used in the following manner. First, the component 1000 may be mounted on the end of the extensible probe 24a. Then, the extensible probe 24a may be retracted into the vacuum compatible radiation shielded transfer container 22a and the transfer container seal in the sealable opening 28a may be closed. The transfer container 22a may be transferred to the ion source vacuum chamber 30 and attached onto the valved opening 38a. The vacuum and inert gas venting connection 63a may be attached to the valve 61a on the transfer container 22a to evacuate the transfer container 22a to a pressure similar to that of the ion source vacuum chamber 30. The transfer container sealable opening 28a and the valved opening 38a may then be opened. The extensible probe 24a is extended until it is in the correct position in the ion source 10. Other services that may be required by the component, such as cooling fluid or electrical lines, are then connected in a conventional manner. If appropriate, other components of the ion source may be connected and the ion source may be operated.

20 Maintenance of the component 1000 may be provided by first retracting the extensible probe 24a into the transfer container 22a and closing the valved opening 38a. Services may then be disconnected and the transfer container 22a may be vented with inert gas. The sealable opening 28a on the transfer container 22a may then be closed. The vacuum and inert gas line 63a may be disconnected from the valve 61a. The transfer container 22a may be disengaged from the valved opening 38a and the transfer container 22a may be transferred to a service area where an inert atmosphere is provided and/or where

5 suitable radiation shielding and remote manipulation hardware is available. Also, the transfer container 22a may be opened to either air or to dry nitrogen, depending on whether the component 1000 is moisture sensitive.

The other extensible probes 24b-c, transfer containers 22b-c, and components 2000, 3000 may be operated in a manner similar to that described above for the extensible probe 10 24a, transfer container 22a, and component 1000. The ion source vacuum chamber 30 may be connected to a vacuum chamber assembly for a mass filter (not shown).

FIG. 5 shows the ion source 10 of FIG. 4 in an operational position with the extensible probes 24a-c extended to connect with the plasma chamber 4000. In addition, the sealable openings 28a-c and the valved openings 38a-c are shown in an open position to 15 facilitate extending the extensible probes 24a-c. The bellows 27a-c have been compressed and three connections 25a, 26a, 25b for services are shown. A baffle 34 also is shown in the ion source vacuum chamber 30. The shape of the baffle 34 and its location and placement within the ion source vacuum chamber 30 downstream of an orifice on the plasma chamber 4000 may help minimize leakage of radioactive phosphorus gas into areas of the ion source 20 vacuum chamber 30 other than the zones where the ion beam must be transported. The ion source 10 may be operated in a conventional manner with a vacuum varying from approximately 10^{-5} torr where the ion beam hits the work piece (not shown) to approximately 10^{-2} torr in the plasma chamber 4000.

FIG. 6 shows an interior portion of an ion source 10' that uses a hot filament 25 cathode 1000' with a plasma chamber 4000' acting as an anode. A vaporizer oven 2000'

5 may contain a solid phosphorus-containing compound 70b' which may be elemental phosphorus. A heater 90b may be used to raise the temperature of the phosphorus material 70b' until a sufficient vapor pressure and gas flow of phosphorus is obtained to operate the ion source plasma chamber 4000'. Phosphorus vapor may be passed into the plasma chamber 4000' through a tube 100b. The vaporizer 2000' may be attached to an
10 extensible probe 24b' and extended towards the plasma chamber 4000'. Alignment may be facilitated by a pair of guides 201b, 202b. The vaporizer 2000' may preferably be unioned, or temporarily joined, to the plasma chamber 4000' using tapered joint 102b, which may make a substantially gas-tight seal and may be self-aligning.

A cathode 1000' may be placed on the extensible probe 24a' and an electrostatic
15 reflector 3000' may be placed on the extensible probe 24c'. The cathode 1000' and the electrostatic reflector 3000' may be mounted on taper joint platforms 601a, 601c' and may be electrically insulated with ceramic insulators 511a, 512a, 513a, 514a, 511c', 512c', 513c', 514c'. A pair of guides 201a, 201c also may be included to assist in the positioning of the extensible probes 24a', 24c'. The guides 201a, 201c preferably may
20 have beveled edges where needed to avoid accidentally entrapping the extensible probes.

It is desirable to avoid leaking radioactive phosphorus gas into areas of the ion source vacuum chamber 30 other than the zones where an ion beam 900 is transported in order to minimize possible contamination to workers during maintenance of the extensible components. Therefore, the vacuum chamber 30 may preferably be separated into two
25 largely isolated volumes, one volume being the zone where the ion beam 900 is located

5 and the second volume being the zone where the extensible probes 24a'-c' enter the vacuum chamber 30. FIG. 6 shows an example in which an extraction electrode 301 and a ground electrode 302 are connected to the plasma chamber 4000' downstream of the plasma chamber 4000'.

The detailed method of preparing the preferred embodiment of the radiopaque,
10 radioactive stent of this invention would be as follows. First, an ordinary non-radioactive, non-radiopaque coronary stent made of stainless steel with dimensions of approximately 2 mm in diameter, 1.5 cm in length may be placed in a vacuum chamber of an unbalanced magnetron sputter coating apparatus. The apparatus may have two sputter sources, one for chromium and one for gold. The chamber may also contain a low energy "Kaufman" type
15 ion source for sputter cleaning parts using an argon ion beam. While the stent rotates about its long axis, an ion source with an argon ion beam current density of approximately ten microamps per cm² at two keV may be directed at the rotating stent for approximately eight to ten minutes to remove the native oxide and to remove approximately 100 to 500 angstroms of stainless steel from the stent's surface for the purpose of making the surface
20 atomically clean. The stent may then be coated with 3000 angstroms of chromium using the first sputter gun for approximately 10 minutes. The stent may then be coated with approximately 12 microns of pure gold using the second sputter gun in a one hour deposition period. During these coating runs, the stent may be biased with 100 volts of D.C., which generally produces better adhesion of each coating.

25 After these coatings, the stent may be removed from the coating apparatus and placed in the end station vacuum chamber of a special-purpose radioactive ion implanter

5 similar to the implanter described above. While rotating, the stent may be exposed to a
fluence of $6 \times 10^9 \text{ P}^{32}/\text{cm}^2$ times pi (3.14159) (to account for the circumference of the stent)
at a kinetic energy of 180 keV. The implantation process, done at an ion beam current
density of approximately one picoampere per cm^2 , may take approximately 50 minutes to
complete. At the conclusion of the implantation process, the stent may have an activity of
10 approximately two microcuries. The stent may then be shipped to a hospital and, after
approximately two weeks (one half-life) on the shelf, it may have an activity of one
microcurie and be ready for an angioplasty procedure.

While the invention has been disclosed in connection with the preferred
embodiments shown and described in detail, various modifications and improvements
15 thereon will become readily apparent to those skilled in the art. Accordingly, the spirit
and scope of the present invention is to be limited only by the following claims.

5 Claims

1. A stent, comprising:
 - a body formed from a non-radioactive structural material;
 - a radiopaque material coating said body; and
 - a beta-emitting radioisotope ion implanted into said radiopaque material.
- 10 2. A stent, according to claim 1, further comprising an adhesion layer coupled to said body and coupled to said radiopaque material.
3. A stent, according to claim 2, wherein said adhesion layer includes at least one material selected from the group consisting of titanium, vanadium, chromium, iron, cobalt and nickel.
- 15 4. A stent, according to claim 2, wherein said body includes a longitudinal portion and a circumferential portion, and wherein said radiopaque material coats both of said portions with substantially even thickness.
5. A stent, according to claim 2, wherein said beta-emitting radioisotope emits substantially no alpha or gamma radiation for use as part of an intra-arterial coronary
20 stent.
6. A stent, according to claim 2, wherein said radiopaque material includes at least one material selected from the group consisting of platinum, iridium, and rhenium.

- 5 7. A stent, according to claim 2, wherein said radiopaque material includes at least one
material selected from the group consisting of gold and tantalum.
8. A stent, according to claim 2, wherein said beta-emitting radioisotope includes
sulfur-35.
9. A stent, according to claim 2, wherein said beta-emitting radioisotope includes
10 phosphorous-32.
10. A stent, according to claim 2, wherein said radiopaque material is between
approximately 1 micron and approximately 5 microns thick.
11. A stent, according to claim 2, wherein said radiopaque material is between
approximately 1 micron and approximately 15 microns thick.
- 15 12. A stent, according to claim 2, wherein said beta-emitting radioisotope is ion
implanted to a depth of less than approximately 3000 angstroms into said radiopaque
material.
13. A stent, according to claim 2, wherein said beta-emitting radioisotope is ion
implanted with a source strength of between approximately 0.1 microcuries and 10
20 microcuries.

- 5 14. A stent, according to claim 2, wherein said beta-emitting radioisotope has a half life
 of less than approximately 100 days.
15. A stent, according to claim 2, wherein said body has a tubular mesh shape.
16. A stent, according to claim 2, wherein said body includes a helical coil.
17. A stent, according to claim 2, wherein said adhesion layer includes a transition
10 metal.
18. A stent, according to claim 2, wherein said adhesion layer is between approximately
 100 angstroms and approximately 3000 angstroms thick.
19. A stent, comprising:
 means for forming a non-radioactive body;
15 means for coupling a radiopaque material to the body; and
 means for ion implanting a beta-emitting radioisotope into the radiopaque
 material.
20. A method of fabricating a stent, comprising:
 forming the stent from a non-radioactive structural material;
20 coupling a radiopaque material to the structural material; and
 ion implanting a beta emitting radioisotope into the radiopaque material.

- 5 21. A method according to claim 20, further comprising coating the structural material with an adhesion layer and then coating the adhesion layer with the radiopaque material.
22. A method according to claim 20, wherein coupling the radiopaque material includes sputtering the radiopaque material.
- 10 23. A method according to claim 20, wherein coupling the radiopaque material includes electroplating the radiopaque material.
24. A method according to claim 20, wherein coupling the radiopaque material includes applying the radiopaque material as a coating with a thickness of less than approximately 15 microns.
- 15 25. A method according to claim 20, further comprising ion implanting the beta emitting radioisotope to a depth in the coating of less than approximately 3000 angstroms.
26. A method according to claim 20, further comprising selecting the beta emitting radioisotope to include phosphorous-32.
27. A method according to claim 20, further comprising selecting the radiopaque
20 material to include at least one material selected from the group consisting of gold, platinum, iridium, tantalum and rhenium.

- 5 28. A method according to claim 21, further comprising selecting the adhesion layer to include at least one transition metal.
29. A method according to claim 21, further comprising selecting the adhesion layer to include at least one material selected from the group consisting of titanium, vanadium, chromium, iron, cobalt and nickel.




FIG. 1




FIG. 1A





FIG. 2
COATED STENT WIRE



PROFILE CODE

FIG. 3

4/6





FIG. 4






FIG. 6



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: A61L 31/00, A61F 2/06	A3	(11) International Publication Number: WO 99/02195 (43) International Publication Date: 21 January 1999 (21.01.99)
(21) International Application Number: PCT/US98/10678 (22) International Filing Date: 26 May 1998 (26.05.98) (30) Priority Data: 60/051,861 7 July 1997 (07.07.97) US 08/912,762 18 August 1997 (18.08.97) US (63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application US Not furnished (CIP) Filed on Not furnished (71) Applicant (for all designated States except US): IMPLANT SCIENCES CORPORATION [US/US]; 107 Audubon Road #5, Wakefield, MA 01880-1246 (US). (72) Inventor; and (75) Inventor/Applicant (for US only): ARMINI, Anthony, J. [US/US]; 5 Skytop Drive, Manchester, MA 01944 (US). (74) Agents: BLODGETT-FORD, Sayoko, J. et al.; Foley, Hoag & Eliot LLP, One Post Office Square, Boston, MA 02109 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 20 May 1999 (20.05.99)
(54) Title: CORONARY STENT WITH A RADIOACTIVE, RADIOPAQUE COATING		
(57) Abstract <p>A stent according to the systems and methods described herein may include a body formed from a non-radioactive structural material, a radiopaque material coating the body, and a beta-emitting radioisotope ion implanted into the radiopaque material. Optionally, an adhesion layer, such as titanium, vanadium, chromium, ion, cobalt, nickel, or some combination or alloy thereof, may be applied to the body to facilitate adhesion of the radiopaque material. The radiopaque material may include platinum, iridium, rhenium, gold, tantalum, or some combination or alloy thereof. The beta-emitting radioisotope may include sulfur-35 or phosphorous-32 and may be ion implanted into the radiopaque material.</p> <div data-bbox="678 1186 1318 1480" data-label="Image"> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

INTERNATIONAL SEARCH REPORT

Inte. onal Application No
PCT/US 98/10678

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61L31/00 A61F2/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61L A61N A61F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	EP 0 819 446 A (ADVANCED CARDIOVASCULAR SYSTEM) 21 January 1998 see column 5, line 6 - line 50; claims ---	1, 2, 7, 19, 27
P, X	HAFELI U O ET AL: "Electrodeposition of radioactive rhenium onto stents to prevent restenosis" BIOMATERIALS, vol. 19, no. 10, May 1998, page 925-933 XP004124453 see abstract --- -/--	1, 2, 7, 19, 27

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

25 March 1999

Date of mailing of the international search report

07/04/1999

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

ESPINOSA, M

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/10678

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>VIOLARIS AG ET AL: "Endovascular stents: a 'break through technology', future challenges"</p> <p>INTERNATIONAL JOURNAL OF CARDIAC IMAGING, vol. 13, February 1997, pages 3-13, XP002075648</p> <p>see page 8 - page 11</p> <p style="text-align: center;">---</p>	1-29
A	<p>OZAKI Y ET AL: "NEW STENT TECHNOLOGIES"</p> <p>PROGRESS IN CARDIOVASCULAR DISEASES, vol. 34, no. 2, September 1996, pages 129-140, XP000764849</p> <p>see page 137 - page 138</p> <p style="text-align: center;">---</p>	1-29
A	<p>EP 0 433 011 A (FISCHELL ROBERT ;FISCHELL TIM A (US)) 19 June 1991</p> <p>see claims</p> <p>& US 5 059 166 A</p> <p>cited in the application</p> <p style="text-align: center;">-----</p>	1-29

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/10678

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0819446 A	21-01-1998	US 5871436 A	16-02-1999
		AU 696973 B	24-09-1998
		AU 2354197 A	29-01-1998
		CA 2206394 A	19-01-1998
		JP 10057382 A	03-03-1998

EP 0433011 A	19-06-1991	US 5059166 A	22-10-1991
		AT 108635 T	15-08-1994
		AT 149365 T	15-03-1997
		AU 624310 B	04-06-1992
		AU 6795390 A	13-06-1991
		CA 2031891 A	12-06-1991
		DE 69010864 D	25-08-1994
		DE 69010864 T	10-11-1994
		DE 69030118 D	10-04-1997
		DE 69030118 T	12-06-1997
		DK 433011 T	31-10-1994
		EP 0593136 A	20-04-1994
		ES 2058822 T	01-11-1994
		ES 2097972 T	16-04-1997
		JP 2803366 B	24-09-1998
		JP 4126139 A	27-04-1992
		US 5176617 A	05-01-1993
